Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HB1011
- Development stage
- Phase 1
- Lead developer
- HieraBio
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Parenteral
01
Overview
HB1011 is an allogeneic myocardium-derived mesenchymal stem cell therapy being developed by HieraBio for the treatment of ischemic cardiomyopathy and myocardial infarction. It consists of stem cells derived from the myocardium, which are designed to repair and regenerate damaged heart tissue. In clinical trials, HB1011 is administered via direct injection into the damaged heart muscle during coronary artery bypass grafting (CABG) surgery. It is currently in Phase I development for ischemic cardiomyopathy.
- Other names
- allogeneic myocardium-derived mesenchymal stem cell therapyallogeneic myocardium-derived mesenchymal stem cells
Beyond the preview
Go deeper on HB1011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HB1011.